ATE199498T1 - Verwendung von leukämieinhibierendem faktor (lif) zur behandlung von tumoren und sarkomen - Google Patents

Verwendung von leukämieinhibierendem faktor (lif) zur behandlung von tumoren und sarkomen

Info

Publication number
ATE199498T1
ATE199498T1 AT93901068T AT93901068T ATE199498T1 AT E199498 T1 ATE199498 T1 AT E199498T1 AT 93901068 T AT93901068 T AT 93901068T AT 93901068 T AT93901068 T AT 93901068T AT E199498 T1 ATE199498 T1 AT E199498T1
Authority
AT
Austria
Prior art keywords
sarcomas
pct
lif
inhibiting factor
treat tumors
Prior art date
Application number
AT93901068T
Other languages
English (en)
Inventor
George Kannourakis
Original Assignee
Amrad Corp Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amrad Corp Ltd filed Critical Amrad Corp Ltd
Application granted granted Critical
Publication of ATE199498T1 publication Critical patent/ATE199498T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2093—Leukaemia inhibitory factor [LIF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT93901068T 1991-12-24 1992-12-24 Verwendung von leukämieinhibierendem faktor (lif) zur behandlung von tumoren und sarkomen ATE199498T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPL016491 1991-12-24
PCT/AU1992/000683 WO1993012806A1 (en) 1991-12-24 1992-12-24 A method for the treatment of tumours and sarcomas

Publications (1)

Publication Number Publication Date
ATE199498T1 true ATE199498T1 (de) 2001-03-15

Family

ID=3775908

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93901068T ATE199498T1 (de) 1991-12-24 1992-12-24 Verwendung von leukämieinhibierendem faktor (lif) zur behandlung von tumoren und sarkomen

Country Status (9)

Country Link
US (1) US5599789A (de)
EP (1) EP0620736B1 (de)
JP (1) JPH07502514A (de)
KR (1) KR940702380A (de)
AT (1) ATE199498T1 (de)
AU (1) AU3251693A (de)
CA (1) CA2104576C (de)
DE (1) DE69231726D1 (de)
WO (1) WO1993012806A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021272A1 (en) * 1993-03-17 1994-09-29 Amrad Corporation Limited A method for treating microbial infection in an animal by administering a composition comprising lif and a cytokine
WO1997016202A1 (en) * 1995-10-27 1997-05-09 Amrad Operations Pty. Ltd. Cytokines and their use in treatment and/or prophylaxis of breast cancer
AU723610B2 (en) * 1995-10-27 2000-08-31 Walter And Eliza Hall Institute Of Medical Research, The Cytokines and their use in treatment and/or prophylaxis of breast cancer
DK3117833T3 (en) * 2005-07-19 2019-03-18 Stemgen S P A Inhibition of Tumor-rich Potential of Tumor Stem Cells with LIF

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4840815A (de) * 1971-09-25 1973-06-15
JPS62112769A (ja) * 1985-11-12 1987-05-23 Tadahiro Shimazu 耐摩耗性、耐食性、耐久性に優れる容射被膜の形成方法
AU609128B2 (en) * 1987-04-02 1991-04-26 Amrad Operations Pty. Limited Leukaemia-inhibitory factor
PT87133B (pt) * 1987-04-02 1992-07-31 Amrad Corp Ltd Metodo de purificacao do factor inibidor da leucemia (lif) e de composicoes farmaceuticas contendo polipeptidos com actividade do lif
DE3822997A1 (de) * 1988-07-07 1990-01-18 Henkel Kgaa Detergensmischung aus nichtionischen und anionischen tensiden und deren verwendung
CA1340748C (en) * 1988-07-13 1999-09-14 Stephen Oroszlan Synthetic hiv protease gene and method for its expression
AU622515B2 (en) * 1989-01-10 1992-04-09 Amrad Operations Pty. Limited Leukaemia inhibitory factor from livestock species and use thereof to enhance implantation and development of embryonic cells
AU623987B2 (en) * 1989-03-07 1992-05-28 Amrad Operations Pty. Limited Metabolic effects of leukaemia inhibitory factor on bone
AU5958090A (en) * 1989-06-29 1991-01-17 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Method for protecting bone marrow against chemotherapeutic drugs and radiation therapy using transforming growth factor beta 1
WO1991007992A1 (en) * 1989-11-24 1991-06-13 Monash University Proliferative action of leukaemia inhibitory factor on satellite cells
GB9004890D0 (en) * 1990-03-05 1990-05-02 Heath John K Leukaemia inhibitory factor
AU635412B2 (en) * 1990-03-20 1993-03-18 Amrad Operations Pty. Limited A method for regulating neuron development and maintenance

Also Published As

Publication number Publication date
US5599789A (en) 1997-02-04
EP0620736A1 (de) 1994-10-26
KR940702380A (ko) 1994-08-20
CA2104576A1 (en) 1993-06-25
WO1993012806A1 (en) 1993-07-08
EP0620736A4 (en) 1995-09-06
EP0620736B1 (de) 2001-03-07
JPH07502514A (ja) 1995-03-16
DE69231726D1 (de) 2001-04-12
AU3251693A (en) 1993-07-28
CA2104576C (en) 1997-04-15

Similar Documents

Publication Publication Date Title
DE59903921D1 (de) Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
ES2235353T3 (es) Naftridonas para inhibir la proteina tirasina quinasa y proliferacion celular mediada por la quinasa del ciclo celular.
DE69317578D1 (de) Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen
CY2431B1 (en) Novel phenanthridines substituted in the 6 position.
BG104599A (en) Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
ATE227133T1 (de) Verwendung von interferon-alpha 8 subtype zur herstellung von medikamenten zur behandlung von viralinfektionen der leber
ATE255896T1 (de) Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen
GR3021411T3 (en) Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles.
DE59703471D1 (de) Betain-geminitenside auf der basis von aminen
DE69830751D1 (de) Polyaromatische Verbindungen zur Behandlung von Herpes-Infektionen
PL338452A1 (en) Novel substituted 6-phenylphenatridines
DE69326250D1 (de) Neuropeptide y antagoniste
ATE179211T1 (de) Menschliche il-3-varianten
MY120976A (en) 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines
ATE382061T1 (de) Mittel zur induktion von apoptosis und zur therapieanwendung
ATE190352T1 (de) Dorsalgewebe beeinflussender faktor und zusammensetzungen
ATE104551T1 (de) S-adenosylmethionin zur behandlung von pankreatitis und der immunabstossung des pankreastransplantates.
ATE231131T1 (de) Verbindungen mit wachtumshormon freisetzenden eigenschaften
DE69231726D1 (de) Verwendung von leukämieinhibierendem faktor (lif) zur behandlung von tumoren und sarkomen
MX9605072A (es) Dispositivo dispensador para pretratamiento.
EP0237829A3 (en) Tetrahydro-3,4-furandiamine-n-n'-platinum complexes
DE69835828D1 (de) Muc-1 derivate und deren verwendung zur behandlung von krebsassoziierter muc-1 mucin induzierter immunosuppression
ATE203162T1 (de) Verfahren zur behandlung von chronischer prostatitis mit 17-beta-n-tertbutylcarbamoyl-4- aza-5 alpha-androst-1-en-3-one
DE69424679D1 (de) Zusammensetzung zur behandlung oder vorbeugung von herpes
ATE60574T1 (de) Hydroxylierte 1,2-diamincyclohexan platinkomplexe.